Inflammatory cytokines and related signaling pathways

Inflammatory cytokines are a diverse group of signaling proteins, including tumor necrosis factors (TNF), interleukins (IL), and interferons (IFN), that serve as critical mediators of the immune response and inflammatory processes (StatPearls, 2023). These cytokines exert their effects by binding to high-affinity cell-surface receptors, which subsequently activate complex intracellular signaling pathways such as the JAK-STAT, NF-κB, and MAPK cascades (Nature Reviews Drug Discovery, 2017). Chronic overproduction or dysregulation of these molecules is central to the pathogenesis of various inflammatory and autoimmune disorders, including rheumatoid arthritis, inflammatory bowel disease, and psoriasis (NIH, 2022). Consequently, these pathways are major therapeutic targets in modern medicine, with interventions ranging from monoclonal antibodies that sequester ligands to small-molecule inhibitors that block downstream signal transduction (PubMed, 2021). Drugs like infliximab and tofacitinib exemplify the clinical application of targeting these pathways to reduce systemic inflammation (FDA, 2023). While these therapies have revolutionized the management of chronic inflammatory diseases, they carry inherent risks of systemic immunosuppression and increased vulnerability to opportunistic infections (PubMed, 2022). Monitoring of these pathways often involves measuring systemic biomarkers like C-reactive protein or specific cytokine levels to assess disease activity and treatment response (Mayo Clinic, 2023). Overall, the modulation of inflammatory cytokine signaling remains a cornerstone of treatment for immune-mediated pathologies.

Other names

Pro-inflammatory cytokinesCytokine signaling cascadesInflammatory mediatorsCytokine-receptor signaling

Therapeutic agents modulate these pathways by neutralizing circulating cytokine ligands, competitively blocking cell-surface receptors, or inhibiting intracellular signaling enzymes like Janus kinases (JAKs) to prevent the transcription of pro-inflammatory genes (Nature Reviews Drug Discovery, 2017; PubMed, 2021).